Tadd Lazarus, MD, Chief Medical Officer, QIAGEN, discusses the importance of companion diagnostics.
Tadd Lazarus, MD, Chief Medical Officer, QIAGEN, discusses the importance of companion diagnostics.
Clinical Pearls I
- Diagnostics provide the foundation of care. Companion diagnostics are no exception.
- Today, about 45% of oncology drugs in the pipeline have a corresponding biomarker. Ten years ago, that number was 5-10%.
Clinical Pearls II
- Companion diagnostics allow clinicians to select the group of patients that will most likely respond to that drug.
- New drugs often have a better safety profile compared with older drugs but must be used selectively due to cost and other factors.
More on diagnostics > >
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More